TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06504875

Intervention type: DRUG
Intervention: Tislelizumab
Description: Tislelizumab 200mg ivd D1

Intervention type: DRUG
Intervention: Interleukin-2
Description: Interleukin 2 100IU HD,QOD d1-d14

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid po, d1-d14

Intervention type: DRUG
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 ivd, d1
Study: NCT05634213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
Study: NCT06098027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]CS0159
Description: Single oral administration of 4mg \[14C\]CS0159
Study: NCT04248764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam roller application
Description: Following the fatigue protocol, foam roller application will be applied to the quadriceps femoris muscle for five minutes in the prone position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage application
Description: Following the fatigue protocol, sports massage will be applied to the quadriceps femoris muscle for five minutes.
Study: NCT05005637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Tuberculosis Drug
Description: ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 4RH (4 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Oral prednisone will be given at the dose of 1 mg/kgBW/day (max 60 mg/day) until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
Study: NCT05878041

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular and genetic screening
Description: Molecular and genetic screening

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular and genetic screening
Description: Molecular and genetic screening
Study: NCT06334562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUGAMMADEX SODIUM 100 Mg in 1 mL
Description: The dose of Sugammadex Sodium 100 Mg in 1 mL is 2mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is 50 μg/kg
Study: NCT06381687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A multi-component, multi-level programme (MoviMusi)
Description: The MoviMusi program will be designed and implemented in each city by the 12 ECEC centres in the intervention group. In addition, the intervention programme will aim to address the main barriers and facilitators identified during the first year (baseline assessment) in relation to movement and music curricular practices. The programme will have three axes:~(1) Training. Educators and families will actively participate in a series of seminars and training workshops on the promotion of PA as a healthy behaviour and the use of music as a didactic resource to strengthen holistic education both inside and outside ECEC. (2) Participation. Each ECEC institution will be supported as they design a movement and music programme to offer children better opportunities to learn about the body, its possibilities of action, and musical skills.(3) Implementation. The specific actions of the MoviMusi Programme will be put into practice in each ECEC institution.
Study: NCT04982367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting balloon catheter
Description: Sirolimus-eluting balloon catheter designed and produced by Acotec

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting balloon catheter
Description: Paclitaxel-eluting balloon catheter (trade name:DHALIA)
Study: NCT06201611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol+ Standard care arm
Description: This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epalrestat + Alpha Lipoic Acid +Standard care
Description: This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care alone
Description: Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
Study: NCT06352567

Intervention type: OTHER
Intervention: European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire
Description: It consists of a total of 20 items each is scored from 1: not at all to 4: very much in a 4-point Likert scale. Individuals are requested to fill out by considering their last week. Sensory, motor, and autonomic subscales are reported within its constructs. A total of 9, 8, and 3 items are referred to as sensory, motor, and autonomic disturbances, respectively
Study: NCT06544122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.
Study: NCT06631001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: Abdominal massage will be administered twice a day for 15 minutes over three days. This intervention aims to evaluate its effects on defecation frequency, gastric residual volume, and abdominal distension.
Study: NCT04846946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hey, Friend
Description: Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP.
Study: NCT06628492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stainless steel printed surgical guide
Description: the patient will wear the stainless steel surgical guide for the insertion of one implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: resin printed surgical guide
Description: the patient will wear the resin surgical guide for insertion of adjacent another implant implant
Study: NCT04706013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxal Phosphate
Description: Oral tablets 50 mg
Study: NCT05963776

Intervention type: DEVICE
Intervention: spirometry
Description: pulmonary function tests using spirometry

Intervention type: DEVICE
Intervention: spirometry
Description: pulmonary function tests using spirometry
Study: NCT05464030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: 5-FU will be administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid will be administered intravenously as per standard of care.
Study: NCT04716946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive durvalumab 1500mg durvalumab via IV infusion over 1 hour, once every 4 weeks (Q4W) for up to a maximum of 6 months (up to 6 doses/cycles) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Radiation therapy will be performed with external beam ionizing radiation in accordance with institutional standard practice. 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist.
Study: NCT05060510

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Take home saliva kit
Description: Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
Study: NCT05248620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Clavulanic 500/125mg or placebo
Description: Prophylactic antibiotic treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin Clavulanic 500/125mg or placebo
Description: Prophylactic antibiotic treatment
Study: NCT05001113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the subxiphoid approach thoracoscopic thymectomy
Description: A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the lateral intercostal approach thoracoscopic thymectomy
Description: Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.
Study: NCT04945837

Intervention type: OTHER
Group type: OTHER
Intervention: self administered questionnaire
Description: longitunidal descriptive study
Study: NCT05916716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium dipyrone
Description: All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium dipyrone
Description: All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
Study: NCT05890742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: In ARM Phase Ib Control group, Sintilimab will be used twice, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310&Sintilimab
Description: In ARM Phase Ib\&III Experimental group，IBI310\&Sintilimab will be used in first cycle, Sintilimab will be used in second cycle(q3w). Radical surgery after neoadjuvant therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310&Sintilimab
Description: In ARM Phase Ib\&III Experimental group，IBI310\&Sintilimab will be used in first cycle, Sintilimab will be used in second cycle(q3w). Radical surgery after neoadjuvant therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Description: In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
Study: NCT05355090

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PP
Description: Protein Pacing three times per day
Study: NCT05702684

Intervention type: OTHER
Intervention: electronic Holistic Needs Assessment (eHNA)
Description: eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.

Intervention type: OTHER
Intervention: electronic Holistic Needs Assessment (eHNA)
Description: eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
Study: NCT05941377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood pressure lowering
Description: For EBPL group, patients are required to keep blood pressure at 100-120 mmHg. For SBPL group, patients are required to keep blood pressure at 120-140 mmHg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood pressure lowering
Description: For EBPL group, patients are required to keep blood pressure at 100-120 mmHg. For SBPL group, patients are required to keep blood pressure at 120-140 mmHg.
Study: NCT06245577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interdisciplinary mesh sacro colpopexy with resection rectopexy
Description: surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interdisciplinary mesh sacro colpopexy with resection rectopexy
Description: surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure
Study: NCT05918133

Intervention type: DRUG
Group type: OTHER
Intervention: PM8002
Description: IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: nab-paclitaxel
Description: IV infusion
Study: NCT04661670

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: occlusal stabilization splints
Description: an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: occlusal stabilization splints
Description: an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
Study: NCT05890742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Description: In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
Study: NCT05592951

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystal Light (once serving)
Description: Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV with amino acids (one serving)
Description: Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV with amino acids (two servings)
Description: Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV with amino acids (three servings)
Description: Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
Study: NCT04849923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training session
Description: Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training session
Description: Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.
Study: NCT04317638

Intervention type: OTHER
Intervention: Lipid profile
Description: 3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.

Intervention type: OTHER
Intervention: Lipid profile
Description: 3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.

Intervention type: OTHER
Intervention: Lipid profile
Description: 3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
Study: NCT06256549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: Titrated to low dose or middle or high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Titrated to 1.0 mg once a week
Study: NCT05377294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method of Levels therapy
Description: MOL therapy aims to help people develop awareness of their personal goals so they can identify incompatibilities and find potential solutions. In MOL, the therapist uses a specific style to help people focus attention on the problem at hand, long enough to consider the issues from different perspectives, including reflection on the associated emotions. This process is usually very experiential and requires the client to be actively engaged in controlling the focus of the session and decision making.